Benjamin Soff

David Karnovsky

Douglas Arthur

Thomas Yeh

Jason Bazinet

Kutgun Maral

Vasily Karasyov

Kannan Venkateshwar

- **Venu Holding Corporation (VENU)** is expected to complete a **$14 million sale-leaseback** of a parking property on its Colorado Springs campus in **early November 2025**.  **[71691_582cecf2f7ae4fffa1dfac9273ace6a5_0]** 
- The property, which cost VENU approximately **$7.7 million** to acquire and improve, is anticipated to generate a **$6 million development profit** to be recorded in **Q4 2025**.  **[71691_582cecf2f7ae4fffa1dfac9273ace6a5_0]** 
- The **$14 million sales price** will be paid with **$8 million in cash** and **$6 million in VENU common stock**, with the company intending to retire the shares into treasury.  **[71691_582cecf2f7ae4fffa1dfac9273ace6a5_0]** 
- Proceeds from this sale are earmarked for the construction of VENU's upcoming amphitheaters in Oklahoma and Texas.  **[71691_582cecf2f7ae4fffa1dfac9273ace6a5_0]**

Venu to Complete $14 Million Sale-Leaseback on Colorado Springs Property

- GeneDx presented data at the International Consortium on Newborn Sequencing (ICoNS) 2025, highlighting its leadership in genomic newborn screening (gNBS) with **more than 22,000 newborns screened** across major U.S. programs.  **[71691_d1afec61760e4ef8bc9607f6469b1854_0]** 
- The company serves as the laboratory partner for the **largest and most comprehensive gNBS efforts in the U.S.**, including the GUARDIAN Study, Early Check's pilot phase, NIH's BEACONS Network, and Florida's Sunshine Genetics Program.  **[71691_d1afec61760e4ef8bc9607f6469b1854_0]** 
- Earlier this year, GeneDx **acquired Fabric Genomics** to enable flexible solutions, accelerate international expansion, and drive further adoption of gNBS.  **[71691_d1afec61760e4ef8bc9607f6469b1854_0]** 
- The GUARDIAN study, powered by GeneDx Infinity™, demonstrates that gNBS is **feasible, scalable**, and can be performed with **short turnaround times, equitable access, and high diagnostic yield**, identifying conditions missed by traditional screening and offering **significant cost savings**.  **[71691_d1afec61760e4ef8bc9607f6469b1854_0]** **[71691_d1afec61760e4ef8bc9607f6469b1854_1]**

GeneDx Showcases Leadership in Genomic Newborn Screening

- **VENU** announced **record-breaking Luxe FireSuites sales** exceeding **$23 million** in the past **60 days**, with **$10.7 million** secured in August and **$12.3 million** in September.  **[71691_c6fbabf860eb4711b5f3ca861c30a853_0]** 
- FireSuite sales demonstrated a **250% year-over-year increase**, reaching **$77.7 million** in fiscal 2024, compared to **$22.2 million** in fiscal 2023.  **[71691_c6fbabf860eb4711b5f3ca861c30a853_0]** 
- The company anticipates **2025 sales to increase at least 100%** over 2024.  **[71691_c6fbabf860eb4711b5f3ca861c30a853_0]** 
- **VENU** projects **$5 billion in premium live entertainment venue development** over the next **36 months**, building on **$1 billion** already underway.  **[71691_c6fbabf860eb4711b5f3ca861c30a853_0]**

VENU Reports Record FireSuites Sales and Strong Growth Projections

- **Copper** has **closed a $28 million Series A financing** round, a combination of equity and debt, **led by Prelude Ventures**.  **[71691_c2939f8c439e409580845f1b75bca203_0]** 
- This new capital will enable Copper to **expand its operations into new markets and products** and scale its technology platform.  **[71691_c2939f8c439e409580845f1b75bca203_0]** 
- Copper's primary product is a **battery-equipped induction range** that provides a performance boost, supports the grid, and avoids expensive electrical upgrades.  **[71691_c2939f8c439e409580845f1b75bca203_0]** **[71691_c2939f8c439e409580845f1b75bca203_1]** 
- The company's business primarily comes from **B2B sales to owners of buildings and real estate portfolios**, including a recent contract with the New York Housing Authority for **10,000 units** and stated interest for an additional **300,000+** units.  **[71691_c2939f8c439e409580845f1b75bca203_0]**

Copper Closes $28 Million Series A Financing

- **Fivespan Partners**, an activist investment firm, has acquired a stake in **The New York Times Company**.  **[71691_84b36c8a723645fcb79209eddaafba6b]** 
- Fivespan is urging the media company to accelerate its use of **artificial intelligence** to expand its subscription base and believes AI could more than **double** the Times' long-term revenue and profit.  **[71691_84b36c8a723645fcb79209eddaafba6b]** 
- The New York Times has taken a **cautious approach to AI**, highlighted by its ongoing lawsuit against OpenAI and Microsoft over copyright issues, despite having already integrated AI in its newsroom and signed a generative AI partnership with Amazon.  **[71691_84b36c8a723645fcb79209eddaafba6b]** 
- The New York Times stock price has risen significantly, gaining **87%** since August 2022, following previous activist involvement.  **[71691_84b36c8a723645fcb79209eddaafba6b]**

NEW YORK TIMES (NYT)